Skip to main content

Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer

Buy Article:

$63.00 plus tax (Refund Policy)

Arsenic, a known human carcinogen, can induce tumors of the skin, urinary bladder, liver and lung etc.. On the other hand, arsenic is also a novel promising anticancer agent, and can be used effectively to treat acute promyelocytic leukemia (APL) and some other tumors. These paradoxical effects of arsenic not only result from direct or indirect influences on the genetic and epigenetic levels, but are also closely correlated with unique arsenic metabolism. This article reviews our recent studies as well as other reports on arsenic metabolism and epigenetic changes of DNA methylation during its metabolism. We also summarize the clinical use of arsenic trioxide (As2O3) to date and discuss new therapeutic strategies such as concurrent arsenic-radiation therapy to achieve local tumor control and enhance the radiosensitivity of solid tumors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Arsenic Toxicity; Carcinogenesis; acute promyelocytic leukemia (APL); anticancer agent; arsenic metabolism; arsenic-radiation therapy; tumors; urinary bladder

Document Type: Research Article

Affiliations: Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa Inage-ku, Chiba, Chiba 263-8555, Japan.

Publication date: 01 September 2008

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more